NBP — NOVABRIDGE BIOSCIENCES (Healthcare >> Biotechnology)
NBP FAQ
What is NBP's ROE?
NOVABRIDGE BIOSCIENCES reports a Return on Equity (ROE) of -143.93%.
What is NBP's dividend yield?
NOVABRIDGE BIOSCIENCES offers a dividend yield of 0.00%.
What is NBP's Deepscope Quality Score?
Deepscope rates NBP's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NBP?
Deepscope's AI Timing Score for NBP is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NBP belong to?
NOVABRIDGE BIOSCIENCES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.53
Price
-0.06
(-3.77%)
Day Change
|
|
|---|
NBP, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.53 |
| PBV / Sector |
5.57 / 4.79
|
| Earning Per Share | -0.40 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
1.30 M
GREAT
|
| Average 1W Daily Value |
0.70 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-11 09:54:37 |
| Symbol | NBP |
| Name | NOVABRIDGE BIOSCIENCES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 115.65 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 183.88 / 8,963.32 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2440 Research Boulevard, Rockville, MD, United States, 20850
Phone: 240 745 6330
Website: https://novabridge.com
Sector: Healthcare >> Biotechnology
Description: NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google